# Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis

> **NCT06072001** · PHASE3 · UNKNOWN · sponsor: **Apurano Pharmaceuticals GmbH** · enrollment: 558 (estimated)

## Conditions studied

- Pain
- Pain Syndrome
- Pain, Chronic
- Chronic Pain
- Chronic Pain Syndrome
- Neuropathic Pain
- Central Neuropathic Pain
- Paraplegia
- Multiple Sclerosis
- Stroke
- Phantom Limb Syndrome With Pain
- Phantom Pain
- Traumatic Brain Injury

## Interventions

- **DRUG:** Adezunap (AP707)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06072001
- **Lead sponsor:** Apurano Pharmaceuticals GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-02
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 558 (ESTIMATED)
- **Last updated:** 2024-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06072001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06072001, "Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT06072001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*